Anti-Mouse CD115 (CSF-1R) Antibody – Purified in vivo GOLD™ Functional Grade

Not available

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

CSF-1R antibody (clone AFS98) recognizes an epitope on mouse CD115.

CD115 (CSF-1R) is expressed on monocytes/macrophages, peritoneal exudate cells, plasmacytoid cells, dendritic cells, and osteoclasts.

CD115 antibody, clone AFS98, recognizes CD115, also known as mouse colony-stimulating factor 1 receptor (CSF-1R and macrophage colony-stimulating factor receptor (M-CSFR). CD115 is a 150kDa single-pass type I membrane protein encoded by the c-fms gene that belongs to the type III protein tyrosine kinase receptor family. CD115 has an immunoglobulin-like extracellular domain, transmembrane domain, and C-terminal tail receptor and is expressed by monocytes, macrophages, plasmacytoid and conventional dendritic cells (DCs), osteoclasts, and their precursors. CD115 is the receptor for CSF1, also known as M-CSF, and IL-34. Binding and signaling through CD115 regulates the proliferation, differentiation, survival, and cytokine-production of monocytes and macrophages^1,2. In addition, CD115 plays a key role in the differentiation and proliferation of osteoclasts as well as their bone resorption activity³. Mutations in CSF-1R are associated with cancer, including myeloid malignancies, Alzheimer’s disease, and other inflammatory and autoimmune diseases⁴. The presence of tumor-associated macrophages (TAMs) expressing CSF-1R correlates with poor survival in various tumor types^5,6, and efforts to eliminate these TAMs using CSF1R small-molecule inhibitors and monoclonal antibodies are currently in clinical trials⁷.

Macrophage colony stimulating factor (M-CSF), IL-34

1. Stanley ER., et al. (1982) Cell. 28:71–81
2. Roussel MF., at al. (1988) Cold Spring Harb Symp Quant Biol. 53:521–530
3. Park-Min, KH., et al. (2020) Exp Mol Med 52, 1239–1254
4. Tak, P. P., at al. (2016) Nat. Rev. Drug Disco. 16, 53–70
5. d’Amore F. (2014) Histopathology. 65:490–500
6. Wei YQ., et al. (2012) PLoS One. 7:e50946
7. Rüttinger D., et al. (2017) J Immunother Cancer. 5(1):53